[ad_1]
The trial showed that the vaccine was well tolerated and did not identify any safety concerns, the company said. An independent committee “found no increased risk of thrombosis or events characterized by thrombosis among the 21,583 participants who received at least one dose of the vaccine,” according to AstraZeneca.
The new data comes from a phase 3 clinical trial conducted in the US, Chile, and Peru. AstraZeneca says it plans to submit the findings to a scientific journal for peer review.
For its part, Oxford said the findings add “to previous trial data from the UK, Brazil and South Africa, as well as real-world impact data from the UK,” according to a university news release. .
As part of the trial, more than 32,000 recruited volunteers of all ages received two doses of the vaccine or a placebo vaccine within a four-week interval.
An emergency investigation by the European Medicines Agency (EMA) concluded last Thursday that the vaccine is “safe and effective” in preventing coronavirus and “is not associated with an increased overall risk of thromboembolic events or blood clots”.
Co-designer of the vaccine and professor of vaccination at the University of Oxford, Sarah Gilbert, praised the data for providing “further confirmation of the safety and efficacy” of the vaccine.
The vaccine’s principal investigator and Professor of Pediatric Infection and Immunity at Oxford University, Andrew Pollard, said the AstraZeneca data was “consistent with the results of the Oxford-led trials,” adding that he expected a “strong impact. against COVID-19 at all ages for people of different backgrounds due to widespread use of the vaccine. “
